Healthcare products company Johnson & Johnson (J&J) (NYSE:JNJ) announced on Wednesday that it has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for TAR-200 for the treatment of BCG-unresponsive high-risk non-muscle-invasive bladder cancer (HR-NMIBC).
The FDA is reviewing the application through its Real-Time Oncology Review (RTOR) programme for faster approval.
TAR-200 is the first and only intravesical drug releasing system for this condition and offers an alternative to radical cystectomy, a surgery that removes the entire bladder.
Clinical data from the Phase 2b SunRISe-1 study showed an 83.5% complete response rate with high durability.
TAR-200 is administered in an outpatient setting and has a low rate of severe side effects.
The FDA granted Breakthrough Therapy Designation to TAR-200 in December 2023.
AstraZeneca secures EU recommendation for Imfinzi in limited-stage small cell lung cancer
CHMP recommends EU approval of Daiichi Sankyo and AstraZeneca's datopotamab deruxtecan
Invenra and Orion partner to develop bispecific antibody cancer therapies
Amgen's BLINCYTO (blinatumomab) monotherapy approved in Europe
ImmunityBio partners with BeiGene for Phase 3 NSCLC trial of ANKTIVA and PD-1 inhibitor
Diatech Pharmacogenetics expands Merck collaboration for colorectal cancer testing